NICE guidance “a real victory” for people with schizophreniaBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7351.1413/a (Published 15 June 2002) Cite this as: BMJ 2002;324:1413
- Alex Vass
The National Institute for Clinical Excellence (NICE) has recommended the more widespread use of atypical antipsychotic drugs for patients with schizophrenia on the grounds that they have fewer side effects and are as effective as the older drugs commonly prescribed for the condition.
Releasing its recommendations after a year long review of over 200 trials, the institute said that older antipsychotic drugs (such as chlorpromazine and haloperidol) were associated with a higher incidence of extrapyramidal side effects (such as parkinsonism, acute dystonic …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial